Novartis COMBI-AD study of Tafinlar+ Mekinist continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
- Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit
- Cure rate modeling which estimates fraction of patients who may not relapse was 54% with adjuvant Tafinlar + Mekinist compared to 37% with placebo
- Updated COMBI-AD data results simultaneously published in Journal of Clinical Oncology
- as monotherapy and in combination for the treatment of subjects with unresectable or metastatic melanoma with a BRAFV600 mutation
- in combination for the adjuvant treatment of patients with Stage III melanoma with a BRAFV600 mutation, following complete resection
- in combination for the treatment of patients with advanced NSCLC with a BRAFV600 mutation
- in combination for the treatment of patients with locally advanced or metastatic ATC with a BRAFV600 mutation